England's "innovation pass" pilot will allow limited access without NICE appraisal - Update
This article was originally published in SRA
Executive Summary
The Department of Health in England will begin piloting its “innovation pass” scheme in April. The scheme will allow certain promising licensed medicines to be used by the National Health Service – for a limited period of time and from a new ring-fenced budget – without undergoing the mandatory cost:benefit appraisal by the country’s health technology assessment body, the National Institute for Health and Clinical Excellence1,2.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.